Phase III study of AJM300 in patients with active ulcerative colitis (2)
Phase of Trial: Phase III
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Carotegrast (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors EA Pharma; Kissei Pharmaceutical
- 30 Jul 2018 Planned End Date changed from 1 Mar 2023 to 1 Dec 2020.
- 12 Jun 2018 Status changed from not yet recruiting to recruiting.
- 06 Jun 2018 Planned initiation date changed from 1 May 2018 to 1 Jun 2018.